menu
    • menu
    [{"orgOrder":0,"company":"CD Pharma","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Probiotic","year":"2010","type":"Inapplicable","leadProduct":"Lactobacillus Paracasei","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"CD Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CD Pharma \/ Post Graduate Institute of Medical Education and Research, Chandigarh","highestDevelopmentStatusID":"9","companyTruncated":"CD Pharma \/ Post Graduate Institute of Medical Education and Research, Chandigarh"},{"orgOrder":0,"company":"SunWay Biotech","sponsor":"National Taiwan University Hospital | Chung Shan Medical University","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"TAIWAN","productType":"Probiotic","year":"2019","type":"Inapplicable","leadProduct":"Lactobacillus Paracasei","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"SunWay Biotech","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SunWay Biotech \/ National Taiwan University Hospital | Chung Shan Medical University","highestDevelopmentStatusID":"1","companyTruncated":"SunWay Biotech \/ National Taiwan University Hospital | Chung Shan Medical University"},{"orgOrder":0,"company":"SunWay Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"TAIWAN","productType":"Probiotic","year":"2019","type":"Inapplicable","leadProduct":"Lactobacillus Paracasei","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"SunWay Biotech","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SunWay Biotech \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"SunWay Biotech \/ Undisclosed"},{"orgOrder":0,"company":"SunWay Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"TAIWAN","productType":"Probiotic","year":"2023","type":"Inapplicable","leadProduct":"Lactobacillus Paracasei","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"SunWay Biotech","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SunWay Biotech \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"SunWay Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Sami-Sabinsa Group","sponsor":"Postbiotics","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"INDIA","productType":"Probiotic","year":"2024","type":"Agreement","leadProduct":"Lactobacillus Paracasei","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Sami-Sabinsa Group","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sami-Sabinsa Group \/ Postbiotics","highestDevelopmentStatusID":"15","companyTruncated":"Sami-Sabinsa Group \/ Postbiotics"},{"orgOrder":0,"company":"Nottingham University Hospitals NHS Trust","sponsor":"VSL Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"UNITED KINGDOM","productType":"Probiotic","year":"2012","type":"Inapplicable","leadProduct":"Lactobacillus Paracasei","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Nottingham University Hospitals NHS Trust","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nottingham University Hospitals NHS Trust \/ VSL Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Nottingham University Hospitals NHS Trust \/ VSL Pharmaceuticals"},{"orgOrder":0,"company":"Northumbria University","sponsor":"International Flavors and Fragrances","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Probiotic","year":"2018","type":"Inapplicable","leadProduct":"Lactobacillus Paracasei","moa":"Undisclosed","graph1":"Neurology","graph2":"Undisclosed","graph3":"Northumbria University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Northumbria University \/ International Flavors and Fragrances","highestDevelopmentStatusID":"1","companyTruncated":"Northumbria University \/ International Flavors and Fragrances"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"SWITZERLAND","productType":"Probiotic","year":"2013","type":"Inapplicable","leadProduct":"Lactobacillus Paracasei","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Undisclosed","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nestle Health Sciences SA \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Nestle Health Sciences SA \/ Undisclosed"},{"orgOrder":0,"company":"Chr. Hansen","sponsor":"University of Copenhagen","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"DENMARK","productType":"Probiotic","year":"2019","type":"Inapplicable","leadProduct":"Lactobacillus Paracasei","moa":"Undisclosed","graph1":"Dental and Oral Health","graph2":"Undisclosed","graph3":"Chr. Hansen","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chr. Hansen \/ University of Copenhagen","highestDevelopmentStatusID":"1","companyTruncated":"Chr. Hansen \/ University of Copenhagen"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Chr. Hansen","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Probiotic","year":"2010","type":"Inapplicable","leadProduct":"Lactobacillus Paracasei","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Chr. Hansen","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Chr. Hansen"},{"orgOrder":0,"company":"Next Gen Pharma","sponsor":"Department of Gastroenterology, Govt. Medical College, Kozhikode, Kerala, India","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Probiotic","year":"2015","type":"Inapplicable","leadProduct":"Lactobacillus Paracasei","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Next Gen Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Next Gen Pharma \/ Department of Gastroenterology, Govt. Medical College, Kozhikode, Kerala, India","highestDevelopmentStatusID":"10","companyTruncated":"Next Gen Pharma \/ Department of Gastroenterology, Govt. Medical College, Kozhikode, Kerala, India"}]

    Find Clinical Drug Pipeline Developments & Deals for Lactobacillus Paracasei

    Menu

    Lactobacillus Paracasei

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Sami-Sabinsa Group

                            India arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Sami-Sabinsa Group

                            India arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lactobacillus Paracasei

                            Therapeutic Area : Gastroenterology

                            Study Phase : Approved FDF

                            Sponsor : Postbiotics

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Sabinsa And Postbiotics Ink Deal for PoZibio Dietary Supplement

                            Details : The distribution agreement aims for the dietary supplement and functional food ingredient PoZibio for age-related digestive health conditions including Leaky Gut Syndrome (LGS).

                            Product Name : PoZibio

                            Product Type : Probiotic

                            Upfront Cash : Undisclosed

                            October 23, 2024

                            Lead Product(s) : Lactobacillus Paracasei

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Approved FDF

                            Sponsor : Postbiotics

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            SunWay Biotech

                            Taiwan arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            SunWay Biotech

                            Taiwan arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lactobacillus Paracasei

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Effect of Vigiis 101 Lactic Acid Bacteria Powder on Body Weight and Body Fat in Overweight Participants

                            Details : Lactobacillus Paracasei is a Probiotic drug candidate, which is currently being evaluated in clinical studies for the treatment of Overweight.

                            Product Name : Undisclosed

                            Product Type : Probiotic

                            Upfront Cash : Inapplicable

                            May 22, 2023

                            Lead Product(s) : Lactobacillus Paracasei

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            SunWay Biotech

                            Taiwan arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            SunWay Biotech

                            Taiwan arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lactobacillus Paracasei

                            Therapeutic Area : Undisclosed

                            Study Phase : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Effects of Vigiis 101-LAB on a Healthy Populations' Gut Microflora

                            Details : Lactobacillus Paracasei is a Probiotic drug candidate, which is currently being evaluated in clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Probiotic

                            Upfront Cash : Inapplicable

                            September 12, 2019

                            Lead Product(s) : Lactobacillus Paracasei

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            SunWay Biotech

                            Taiwan arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            SunWay Biotech

                            Taiwan arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lactobacillus Paracasei

                            Therapeutic Area : Undisclosed

                            Study Phase : Undisclosed

                            Sponsor : National Taiwan University Hospital | Chung Shan Medical University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Effects of Vigiis 101-LAB on a Healthy Populations' Gut Microflora, Peristalsis, Immunity, and Anti-oxidative ...

                            Details : Lactobacillus Paracasei is a Probiotic drug candidate, which is currently being evaluated in clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Probiotic

                            Upfront Cash : Inapplicable

                            August 06, 2019

                            Lead Product(s) : Lactobacillus Paracasei

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Undisclosed

                            Sponsor : National Taiwan University Hospital | Chung Shan Medical University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Chr. Hansen

                            Denmark arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Chr. Hansen

                            Denmark arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lactobacillus Paracasei

                            Therapeutic Area : Dental and Oral Health

                            Study Phase : Undisclosed

                            Sponsor : University of Copenhagen

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Effect of 12 Months Supplementation With a Symbiotic Lozenge on Caries Increment in Healthy Children

                            Details : Lactobacillus Paracasei is a Probiotic drug candidate, which is currently being evaluated in clinical studies for the treatment of Dental Caries.

                            Product Name : Undisclosed

                            Product Type : Probiotic

                            Upfront Cash : Inapplicable

                            April 26, 2019

                            Lead Product(s) : Lactobacillus Paracasei

                            Therapeutic Area : Dental and Oral Health

                            Highest Development Status : Undisclosed

                            Sponsor : University of Copenhagen

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Northumbria University

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Northumbria University

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lactobacillus Paracasei

                            Therapeutic Area : Neurology

                            Study Phase : Undisclosed

                            Sponsor : International Flavors and Fragrances

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            The Cognitive Effects of 6 Weeks Administration With a Probiotic

                            Details : Lactobacillus Paracasei is a Probiotic drug candidate, which is currently being evaluated in clinical studies for the treatment of Cognition Disorders.

                            Product Name : Undisclosed

                            Product Type : Probiotic

                            Upfront Cash : Inapplicable

                            July 26, 2018

                            Lead Product(s) : Lactobacillus Paracasei

                            Therapeutic Area : Neurology

                            Highest Development Status : Undisclosed

                            Sponsor : International Flavors and Fragrances

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Next Gen Pharma

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Next Gen Pharma

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lactobacillus Paracasei

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase III

                            Sponsor : Department of Gastroenterology, Govt. Medical College, Kozhikode, Kerala, India

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study to Determine Efficacy of Probiotics in Irritable Bowel Syndrome

                            Details : Lactobacillus Paracasei is a Probiotic drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Irritable Bowel Syndrome.

                            Product Name : Undisclosed

                            Product Type : Probiotic

                            Upfront Cash : Inapplicable

                            September 10, 2015

                            Lead Product(s) : Lactobacillus Paracasei

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase III

                            Sponsor : Department of Gastroenterology, Govt. Medical College, Kozhikode, Kerala, India

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Nestle Health Sciences SA

                            Switzerland arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Nestle Health Sciences SA

                            Switzerland arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lactobacillus Paracasei

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Study Phase : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Probiotic Administration and Perennial Allergic Rhinitis

                            Details : Lactobacillus Paracasei is a Probiotic drug candidate, which is currently being evaluated in clinical studies for the treatment of Rhinitis, Allergic, Perennial.

                            Product Name : Undisclosed

                            Product Type : Probiotic

                            Upfront Cash : Inapplicable

                            January 30, 2013

                            Lead Product(s) : Lactobacillus Paracasei

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Highest Development Status : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Nottingham University Hospitals NHS Trust

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Nottingham University Hospitals NHS Trust

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lactobacillus Paracasei

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Study Phase : Phase II

                            Sponsor : VSL Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            VSL#3 and Spontaneous Bacterial Peritonitis

                            Details : Lactobacillus Paracasei is a Probiotic drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Liver Cirrhosis.

                            Product Name : Undisclosed

                            Product Type : Probiotic

                            Upfront Cash : Inapplicable

                            October 05, 2012

                            Lead Product(s) : Lactobacillus Paracasei

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Highest Development Status : Phase II

                            Sponsor : VSL Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            CD Pharma

                            Italy arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            CD Pharma

                            Italy arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lactobacillus Paracasei

                            Therapeutic Area : Neurology

                            Study Phase : Phase II/ Phase III

                            Sponsor : Post Graduate Institute of Medical Education and Research, Chandigarh

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Secondary Prophylaxis of Hepatic Encephalopathy With a Probiotic Preparation

                            Details : Lactobacillus Paracasei is a Probiotic drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Hepatic Encephalopathy.

                            Product Name : Undisclosed

                            Product Type : Probiotic

                            Upfront Cash : Inapplicable

                            April 26, 2010

                            Lead Product(s) : Lactobacillus Paracasei

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Post Graduate Institute of Medical Education and Research, Chandigarh

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth